Advaxis Will Present at Rodman & Renshaw Annual Healthcare Conference

Advaxis Will Present at Rodman & Renshaw Annual Healthcare Conference

Advaxis, Inc.Diana Moore, 609-452-9814Director, Investor Relations & Business Development

., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Thomas Moore, Chairman and CEO of Advaxis, will present at the Rodman & Renshaw 14 Annual Healthcare Conference on September 10 from 4:30-4:55pm EST in the Palm Room of the Waldorf=Astoria Hotel in New York.

Slides from the presentation will be available on the following the presentation.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.

In April 2012, Advaxis’ lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the .

ADXS-HPV is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neckcancer (University of Liverpool/CRUK UK study, Clinical Trials.gov Identifier NCT0CT01598792). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the , , the , the , the , the , and others. For more information please visit: | |

.

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.